Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PPP5C | P53041 | 2/20 | 0.37 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22018450 | 0.87 | CYP1A2 (0.46) | HRH3CYP1A2TDP1TPSAB1TPSD1 | |
| SCHEMBL22018451 | 0.84 | TPSAB1 (0.50) | TPSAB1TPSD1TPSG1HTT | |
| SCHEMBL21428432 | 0.84 | LMNA (0.47) | CYP1A2TDP1SMN1; SMN2TPSAB1TPSD1 | |
| SCHEMBL8262689 | 0.83 | GAA (0.44) | HRH3RECQLTSHRGPR119USP2 | |
| SCHEMBL31167957 | 0.82 | HSD11B1 (0.46) | HRH3GPR119TPSAB1TPSD1TPSG1 | |
| SCHEMBL19491339 | 0.82 | CYP1A2 (0.42) | HRH3RECQLTSHRCYP1A2TDP1 | |
| SCHEMBL21428419 | 0.82 | LMNA (0.50) | CYP1A2TDP1TPSAB1TPSD1TPSG1 | |
| SCHEMBL8266944 | 0.80 | TSHR (0.55) | HRH3RECQLTSHRCYP1A2USP2 | |
| SCHEMBL15219283 | 0.79 | HTT (0.53) | HRH3TPSAB1TPSD1TPSG1HTT | |
| SCHEMBL4283947 | 0.79 | TPSAB1 (0.51) | HRH3CYP1A2TDP1TPSAB1TPSD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Epizyme, Inc. | 2023-02-16 | — | — | US | disclosed |
| WO-2020037079-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | NSD1, NSD3, EHMT1 | HRH3 2481/4885RECQL 2777/4885TSHR 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.